Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Patient Preference for Early Onset of Efficacy in Migraine Prevention
Headache
Headache Posters (7:00 AM-5:00 PM)
127
To determine the extent that patients with migraine value the early onset of efficacy of preventive migraine treatments.
Eptinezumab (anti-calcitonin gene-related peptide monoclonal antibody) was associated with an absolute therapeutic benefit of reducing migraine-likelihood on Day-1 post-infusion by 14% and 8% compared with placebo in patients with chronic migraine (CM; PROMISE-2 study) and episodic migraine (EM; PROMISE-1 study), respectively.
Adults (≥18yr) with CM or EM self-reporting ≥4 monthly migraine days (MMDs) for ≥3 months, with migraine history for ≥12 months, completed a thresholding exercise (comparing 2 hypothetical treatments by varying 2 key attributes) to ascertain the relative value of migraine prevention on Day-1 post-dosing compared with meaningful reductions in MMDs in the first month post-dosing. Two frames were presented: (1) fixed first-month MMD reduction and varied migraine likelihood on Day-1 post-dosing; (2) fixed migraine likelihood on Day-1 post-dosing and varied first-month MMD reduction.
101 participants (mean age, 50.6yr; 80% female) were included. In participants with CM (n=55), 58.0% considered a 14% migraine-likelihood reduction on Day-1 post-dosing to be at least as important as a reduction of 2 MMDs, and 74.0% indicated that an ≥2-MMD reduction (mean, 5.0) had an equivalent value to a 14% migraine-likelihood reduction on Day-1 post-dosing. In participants with EM (n=35), 51.4% considered an 8% migraine-likelihood reduction on Day-1 post-dosing to be at least as important as a reduction of 1 MMD, and 68.6% indicated that an ≥1-MMD reduction (mean, 2.7) had an equivalent value to an 8% migraine-likelihood reduction on Day-1 post-dosing.
Most patients considered the early onset of migraine-preventive efficacy to be meaningful. Regardless of choice frame, the magnitude of reduction of migraine-likelihood offered by eptinezumab on Day-1 post-infusion was at least as important to patients as clinically relevant reductions in MMDs in the first month after treatment.
Authors/Disclosures
Paul Winner, DO, FÂ鶹´«Ã½Ó³»­ (Palm Beach Headache Ctr)
PRESENTER 		Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for lilly. The institution of Dr. Winner has received research support from Amgen. The institution of Dr. Winner has received research support from Allergan. The institution of Dr. Winner has received research support from Lundbeck . The institution of Dr. Winner has received research support from Novartis. The institution of Dr. Winner has received research support from Lilly. The institution of Dr. Winner has received research support from Teva. The institution of Dr. Winner has received research support from Supernus. The institution of Dr. Winner has received research support from Biogen. The institution of Dr. Winner has received research support from Avinar. The institution of Dr. Winner has received research support from SAMUS.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Jessica Ailani, MD, FÂ鶹´«Ã½Ó³»­ (Medstar Georgetown Neurology) Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.